We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.53 | 1.07% | 50.10 | 50.08 | 50.50 | 50.36 | 49.9508 | 50.23 | 1,603,703 | 00:15:37 |
By Michael Dabaie
Voyager Therapeutics Inc. (VYGR) said it restructured its gene therapy relationship with Sanofi Genzyme.
Voyager said it is gaining worldwide rights to the VY-HTT01 Huntington's disease program and ex-U.S. rights to the VY-FXN01 Friedreich's ataxia program. Voyager is, in turn, transferring the ex-U.S. rights to VY-FXN01 to Neurocrine Biosciences (NBIX) under the terms of a collaboration agreement.
Sanofi Genzyme is obtaining exclusive option rights to select novel AAV capsids owned or controlled by Voyager for exclusive use for up to two non-central nervous system indications, Voyager said.
Voyager agreed to make a $10 million upfront payment to Sanofi Genzyme, which is partially offset by a $5 million payment from Neurocrine Biosciences to Voyager. An additional $10 million milestone payment is due to Sanofi Genzyme from Voyager upon filing of an investigational new drug application for VY-HTT01.
To focus its resources on the now wholly owned Huntington's disease program, Voyager said it would seek a partner to advance its preclinical program for SOD1 amyotrophic lateral sclerosis. Voyager said it no longer expects to file an IND application for its VY-SOD102 in 2019.
Voyager shares were down 3% to $23.41 premarket.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
June 17, 2019 08:34 ET (12:34 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions